Q2 2025 Management View Eric M. Dube, President and CEO, described Q2 2025 as "a standout for Travere, a reflection of strong ...

Citi raised the firm’s price target on Travere Therapeutics (TVTX) to $34 from $32 and keeps a Buy rating on the shares. The firm sees meaningful ...

FILSPARI net product sales increased to $71.9M in Q2 from $55.9M in Q1, with new patient start forms rising to 745 from 703. Total revenue rose from $81.7M in Q1 to $114.4M in Q2, boosted by ...

Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $30 and keeps an Outperform rating on the ...

After meeting with the FDA, Company to submit a supplemental New Drug Application (sNDA) to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in ...

In clinical studies, elevations in aminotransferases (ALT or AST) of at least 3-times the Upper Limit of Normal (ULN) have been observed in up to 3.5% of FILSPARI-treated patients, including cases ...

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference New data from Phase 2 SPARTAN Study show antifibrotic and anti-inflammatory action of ...

--Travere Therapeutics, Inc., today announced that the U.S. Food and Drug Administration has granted full approval to FILSPARI ® to slow kidney function decline in adults with primary IgAN who ...

The Food and Drug Administration (FDA) has granted full approval to Filspari ® (sparsentan) to slow kidney function decline in adults with primary immunoglobulin A (IgA) nephropathy who are at ...

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to ...

Concomitant use of FILSPARI with potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes, or other drugs that raise serum potassium levels may result in hyperkalemia.

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation ...